Immunic, Inc. (NASDAQ:IMUX) Given Consensus Rating of “Buy” by Analysts

Shares of Immunic, Inc. (NASDAQ:IMUX) have earned an average recommendation of “Buy” from the eleven research firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and three have issued a strong buy rating on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $47.5714.

A number of research analysts recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Immunic in a research report on Friday, May 29th. HC Wainwright restated a “buy” rating and set a $22.00 price objective (up from $5.00) on shares of Immunic in a research report on Thursday, April 30th. Roth Mkm restated a “buy” rating and set a $19.00 price objective on shares of Immunic in a research report on Thursday, May 14th. Guggenheim assumed coverage on shares of Immunic in a research report on Tuesday, March 24th. They set a “buy” rating and a $70.00 price objective on the stock. Finally, Lifesci Capital upgraded shares of Immunic to a “strong-buy” rating in a research report on Monday, May 4th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. CTC Alternative Strategies Ltd. bought a new position in Immunic during the first quarter valued at approximately $27,000. Qube Research & Technologies Ltd purchased a new stake in Immunic during the third quarter valued at approximately $29,000. ADAR1 Capital Management LLC purchased a new stake in Immunic during the first quarter valued at approximately $33,000. Two Sigma Investments LP purchased a new stake in Immunic during the third quarter valued at approximately $52,000. Finally, Seven Fleet Capital Management LP purchased a new stake in Immunic during the fourth quarter valued at approximately $83,000. Institutional investors own 51.82% of the company’s stock.

Immunic Stock Performance

Shares of IMUX opened at $12.77 on Friday. The stock has a market cap of $173.93 million, a PE ratio of -2.29 and a beta of 1.37. Immunic has a fifty-two week low of $5.06 and a fifty-two week high of $15.77. The firm’s 50-day simple moving average is $11.78 and its two-hundred day simple moving average is $9.25.

Immunic (NASDAQ:IMUX) last issued its earnings results on Wednesday, May 13th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.37). Equities research analysts predict that Immunic will post -4.57 EPS for the current year.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.